The Priority Review

Tag

ER+

1 story

  1. Clinical trials

    Pfizer registers Phase 3 trial of atirmociclib plus giredestrant in ER+ HER2- early breast cancer

    The study plans to enroll 3800 participants and randomize them 1:1 to receive atirmociclib plus giredestrant or placebo plus giredestrant. It is scheduled to begin on December 1, 2026, with a primary completion date of April 13, 2032.